Navigation Links
Sangamo BioSciences Reports First Quarter 2013 Financial Results
Date:5/8/2013

s were $8.2 million for the first quarter of 2013, compared to $7.3 million for the same period in 2012. The increase in research and development expenses was primarily due to increased external expenses related to our preclinical programs partially offset by lower clinical trials and manufacturing expenses for our SB-728-T HIV/AIDS program. General and administrative expenses were $3.3 million for the first quarter of 2013 and $3.2 million for the same period in 2012.

Total operating expenses for the first quarter of 2013 were $11.5 million, compared to $10.5 million for the same period in 2012.

Recent Highlights

  • Presentation at CROI 2013 of New Clinical Data Demonstrating Persistent Immune System Reconstitution After Treatment With ZFN Therapeutic® SB-728-T.  In March 2013, the Company announced new data from its program to develop a 'functional cure' for HIV/AIDS, in a presentation at the 20th Conference on Retroviruses and Opportunistic Infections (CROI). The data, from the SB-728-T Phase 1 study (SB-728-902, Cohorts 1-3), demonstrated that SB-728-T treatment of HIV-infected subjects leads to durable reconstitution of the immune system driven by increases in total CD4+ central memory T-cells (TCM) and CCR5-protected TCM. TCM are long-lived, self-renewing cells that have the ability to remember and react against foreign antigens including HIV. The data also demonstrated that certain cell surface marker and gene expression profiles may predict which patients will likely respond best to SB-728-T treatment. 
    The Company has two ongoing Phase 2 clinical trials (SB-728-902 Cohort 5 and SB-728-1101) designed to evaluate the relationship of the level of engraftment of T-cells in which both copies of the CCR5 gene has been modified by SB-728 (biallelic engraftment) and reduction in viral load.  Sangamo expects to present preliminary data from these trials on May 15, 2013, at the Annual Meeti
    '/>"/>

  • SOURCE Sangamo BioSciences, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
    2. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
    3. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
    4. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
    5. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
    6. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
    7. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
    8. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
    9. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
    10. Neurocrine Biosciences Reports First Quarter 2012 Results
    11. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... , August 29, 2014 ... Oil Market by Extraction type (SFE, Cold Pressed, ... Personal Care, Pharmaceutical, Food Supplements, Fragrance, & Others) - ... MarketsandMarkets, defines and segments the Amaranth Seed Oil ... market size in terms of value. The Amaranth ...
    (Date:8/29/2014)... --  Vittamed Corporation , a neurodiagnostics medical device company based ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, ... " Teo Forcht Dagi is an experienced ... venture capital," said Remis Bistras , President and CEO ... strategic, and entrepreneurial expertise to our Board." Dr. ...
    (Date:8/29/2014)... 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a workshop ... New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists will ... that hyperspectral imaging can bring to examination procedures. ... Director of Product Development at ChemImage, will host ...
    Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
    ... 16, 2011  Kensey Nash Corporation (NASDAQ: KNSY ) ... to enter into non-binding mediation in an attempt to resolve ... Angio-Seal vascular closure device, as well as other related claims. ... are currently to be paid, and should since 2007 have ...
    ...  Pharmasset, Inc. (Nasdaq: VRUS ) announced today ... QUANTUM Phase 2b trial of the guanine nucleotide analog ... containing PSI-938. There are 235 individuals with hepatitis C ... with PSI-938 alone or in combination with PSI-7977 or ...
    Cached Medicine Technology:Kensey Nash to Enter Into Mediation with St. Jude Medical over Angio-Seal Contract Disputes 2Kensey Nash to Enter Into Mediation with St. Jude Medical over Angio-Seal Contract Disputes 3Kensey Nash to Enter Into Mediation with St. Jude Medical over Angio-Seal Contract Disputes 4Pharmasset Announces Intent to Amend QUANTUM Trial 2Pharmasset Announces Intent to Amend QUANTUM Trial 3
    (Date:8/30/2014)... 30 August 2014: Transvenous lead extraction (TLE) is clinically ... data from the European Lead Extraction ConTRolled (ELECTRa) registry ... 2014 by Dr Maria Grazia Bongiorni, chair of the ... of cardiac implantable electronic devices (CIED) implant procedures has ... number of complications has increased and leads are often ...
    (Date:8/30/2014)... August 30, 2014 Top10BestSEOHosting.com is ... researchers have announced that HostGator.com http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ... current market. Also, they has announced that Bluehost ... , Hostgator, one of the Top 10 ... of cheap Windows hosting, and it offers rich ...
    (Date:8/30/2014)... 30, 2014 LiveStreamingFitness.com, a company dedicated to ... healthy lifestyle resources, is proud to announce it has been ... at home fitness solutions by ABC’s Good Morning America. ... on ABC’s Good Morning America, “Live Streaming Fitness is the ... your day by streamlining your workout…to boot camp at Life ...
    (Date:8/30/2014)... (PRWEB) August 30, 2014 McLeod's Sunset ... service auto repair shop with strong ties to the community ... is happy to announce they have been chosen by ... pick for auto repair. , Tim McLeod’s father, Norris ... Service sixty years ago. Although his son, Tim runs the ...
    (Date:8/30/2014)... FL (PRWEB) August 30, 2014 Zensah®, the ... Camo Compression Leg Sleeve . The camo sleeves are ... Leg Sleeve collection. The camo line includes classic colors ... and magenta. , Known as tibial stress syndrome, shin ... of the lower leg. Swollen and irritated muscles, stress fractures, ...
    Breaking Medicine News(10 mins):Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3Health News:Top10BestSEOHosting.com: HostGator.com Is The Best Windows Hosting Supplier 2Health News:LiveStreamingFitness.com is New Trend In Fitness 2Health News:McLeod's Sunset Park Auto Service Celebrates 60 Years Honored with Best of South Tampa 2Health News:Camo Compression Leg Sleeves Provide Shin Splint Relief for Runners 2
    ... Education Office of the European Association of Urology is ... & Progress, to be held during the 24th Annual ... Education & Progress presents notable technological innovations in urological ... the diagnosis and therapy of diseases by using miniaturised ...
    ... a conversation this country desperately needs about how to reduce ... setting a goal of universal coverage and initiating a public ... right approach. His inclusive brand of leadership makes the ... us to heed the call and to pursue comprehensive reform ...
    ... 9.3 at United States and Canadian Academy of ... part of the Elekta Group and leading provider ... today announced the introduction of PowerPath version 9.3, ... be demonstrated at USCAP conference in Boston, March ...
    ... they think they,re better able to play sports, be ... -- Compared to glasses, contact lenses improve how children ... and their acceptance among friends, a study of 484 ... effect of spectacle wear on self-perception and the perception ...
    ... Inc. (NYSE: MED ) announced today that it ... for the period ended December 31, 2008 on Thursday, March ... Company will hold a conference call and web cast to ... a.m. ET.Interested parties can access the call by dialing (877) ...
    ... Medifast, Inc. (NYSE: MED ), a ... announced the appointment of John P. Daniels and Sr. ... With the addition of Mr. Daniels and Sr. ... of fourteen members, ten of which are classified as ...
    Cached Medicine News:Health News:Education and progress at the 24th Annual EAU Congress in Stockholm 2Health News:Impac Software Introduces PowerPath(R) Version 9.3 AT USCAP 2Health News:Impac Software Introduces PowerPath(R) Version 9.3 AT USCAP 3Health News:Contact Lenses Boost Kids' Self-Image 2Health News:Medifast, Inc. to Announce Fourth Quarter and Fiscal Year 2008 Financial Results on Thursday, March 12, 2009 2Health News:Medifast, Inc. Announces Appointment of Two Additional Independent Board Members 2Health News:Medifast, Inc. Announces Appointment of Two Additional Independent Board Members 3Health News:Medifast, Inc. Announces Appointment of Two Additional Independent Board Members 4
    ... TheraSeed® Pd-103 implant is a combination of ... visibility that makes TheraSeed® treatment an ideal ... be confident that every TheraSeed® implant order ... which is required by clinicians who must ...
    ... designed to help you achieve one important ... procedure. All needles are engineered for exceptional ... for smooth entry and exit. A broad ... an ideal match with procedural needs and ...
    ... a combination of innovative design, consistently reliable ... I-125 implant an ideal choice for your ... every BrachySource I-125 implant order is backed ... required by clinicians who must meet the ...
    ... drainage from the ureteropelvic junction to the ... segment with no sideports prevents postoperative narrowing ... of the ureteral wall to the stent. ... one-time use. CAUTION: Periodic evaluation is advised; ...
    Medicine Products: